Josh is a Partner on the Public Equity team focusing on Biotech and joined the firm in 2021. Josh has over 20 yrs of investing experience in both Biotech and Pharmaceuticals. Prior to joining OrbiMed, Josh was a Senior Analyst covering Biotech and Pharmaceuticals at HealthCor Management. Previously, he covered the same sectors as a buyside Analyst at Millennium, Citadel, Diamondback and ProMed. Josh holds a B.S. in Operations Research with a concentration in Engineering Management Systems from the Fu Foundation School of Engineering and Applied Science at Columbia University. Outside the office, Josh is a long time Knicks fan and enjoys skiing with his two daughters.